Cell Source, Inc. (CLCS)
OTCMKTS · Delayed Price · Currency is USD
0.4000
-0.0610 (-13.23%)
Jul 25, 2025, 1:50 PM EDT

Cell Source Company Description

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance.

Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses.

The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases.

Cell Source, Inc. is headquartered in New York, New York.

Cell Source, Inc.
Cell Source logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees1
CEOItamar Shimrat

Contact Details

Address:
57 West 57th Street
New York, Nevada 10019
United States
Phone646 416 7896
Websitecell-source.com

Stock Details

Ticker SymbolCLCS
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS15114L1044
SIC Code2836

Key Executives

NamePosition
Itamar ShimratChief Executive Officer, President and Chief Financial Officer
Dr. Dennis M. Brown B.Sc., M.A., Ph.D.Executive Chairman